Your browser is no longer supported. Please, upgrade your browser.
CBAY CymaBay Therapeutics, Inc. daily Stock Chart
CBAY [NASD]
CymaBay Therapeutics, Inc.
Index- P/E- EPS (ttm)-1.43 Insider Own0.20% Shs Outstand69.10M Perf Week-6.74%
Market Cap114.71M Forward P/E- EPS next Y-1.06 Insider Trans7.80% Shs Float64.46M Perf Month-10.75%
Income-92.80M PEG- EPS next Q-0.39 Inst Own92.00% Short Float11.91% Perf Quarter0.00%
Sales- P/S- EPS this Y-59.00% Inst Trans-3.19% Short Ratio4.41 Perf Half Y-71.48%
Book/sh3.09 P/B0.54 EPS next Y29.30% ROA-39.30% Target Price2.31 Perf Year-85.94%
Cash/sh3.16 P/C0.52 EPS next 5Y- ROE-42.40% 52W Range1.29 - 14.00 Perf YTD-15.31%
Dividend- P/FCF- EPS past 5Y-15.50% ROI- 52W High-88.14% Beta1.39
Dividend %- Quick Ratio13.10 Sales past 5Y- Gross Margin- 52W Low28.68% ATR0.12
Employees43 Current Ratio13.10 Sales Q/Q- Oper. Margin- RSI (14)46.20 Volatility7.51% 7.00%
OptionableYes Debt/Eq0.00 EPS Q/Q-21.80% Profit Margin- Rel Volume0.64 Prev Close1.65
ShortableYes LT Debt/Eq0.00 EarningsFeb 27 Payout- Avg Volume1.74M Price1.66
Recom2.80 SMA202.44% SMA50-7.56% SMA200-67.59% Volume1,108,204 Change0.61%
Nov-26-19Downgrade ROTH Capital Buy → Neutral $22 → $2
Nov-26-19Downgrade Raymond James Strong Buy → Mkt Perform
Nov-26-19Downgrade H.C. Wainwright Buy → Neutral $16 → $2
Nov-26-19Downgrade Cantor Fitzgerald Overweight → Neutral $20 → $2
Nov-25-19Downgrade SunTrust Buy → Hold
Nov-25-19Downgrade Stifel Buy → Hold
Nov-25-19Downgrade Evercore ISI Outperform → In-line
Jun-25-19Initiated Stifel Buy
Jun-12-19Upgrade Raymond James Outperform → Strong Buy
May-14-19Initiated Citigroup Buy $21
Feb-06-19Initiated B. Riley FBR Neutral $9
Jun-28-18Initiated Raymond James Outperform
Jun-06-18Reiterated H.C. Wainwright Buy $21 → $23
Feb-13-18Initiated Evercore ISI Outperform
Jan-25-18Resumed ROTH Capital Buy $27
Jan-24-18Reiterated H.C. Wainwright Buy $12 → $18
Aug-23-17Initiated Leerink Partners Outperform $12
Aug-18-17Initiated SunTrust Buy $15
Jul-20-17Reiterated Oppenheimer Outperform $8 → $15
Jun-23-17Initiated Oppenheimer Outperform $8
Feb-05-20 11:52AM  Steven Cohen Renews His Interest in Verastem GuruFocus.com
Jan-29-20 04:15PM  CymaBay Publishes Shareholder Letter GlobeNewswire
Jan-15-20 02:25PM  Edited Transcript of CBAY earnings conference call or presentation 5-Nov-19 9:30pm GMT Thomson Reuters StreetEvents
Jan-10-20 09:21AM  CymaBay Therapeutics Enters Oversold Territory Zacks
Dec-31-19 11:48AM  These Falling Knives May Be Worth Catching GuruFocus.com
Dec-17-19 10:31AM  Gilead (GILD) Announces Top-Line Results From NASH Study Zacks -8.99%
Dec-10-19 03:36PM  Genfit Hopes to Buck the Odds With NASH Drug GuruFocus.com
Dec-09-19 06:09AM  Should You Take Comfort From Insider Transactions At CymaBay Therapeutics, Inc. (NASDAQ:CBAY)? Simply Wall St.
Dec-08-19 07:09PM  Is CymaBay Therapeutics Inc (CBAY) Going To Burn These Hedge Funds ? Insider Monkey
Nov-29-19 11:24AM  The Zacks Analyst Blog Highlights: Intercept, CymaBay, Amgen, Global Blood Therapeutics and ChemoCentryx Zacks
08:41AM  NASH Scorecard Year to Date: The Winners and the Losers Zacks
Nov-27-19 10:09AM  Biotech Stock Roundup: CBAY Falls, CCXI Gains, Amgen Acquires Otezla & More Zacks
Nov-26-19 11:07AM  Company News For Nov 26, 2019 Zacks +24.81%
08:24AM  Intercept's (ICPT) NDA for NASH Drug Gets Priority Review Zacks
08:06AM  The Daily Biotech Pulse: ChemoCentryx Triples On Data Readout, Global Blood Given FDA Nod, Positive Safety Review For Genfit's NASH Drug Benzinga
Nov-25-19 04:20PM  This Biotech Popped After Its Rival Crashed 76% On A Scrapped Test Investor's Business Daily -76.04%
09:14AM  UPDATE 2-CymaBay Therapeutics scraps two studies of liver drug; shares plunge Reuters
08:47AM  CymaBay Therapeutics scraps liver disease studies; shares plunge Reuters
08:34AM  CymaBay shares fall 77% on halted trial MarketWatch
08:00AM  CymaBay Therapeutics Halts Clinical Development of Seladelpar GlobeNewswire
Nov-22-19 03:22PM  3 Strong Buy Biotech Stocks to Watch After Stifel Healthcare Conference TipRanks +6.12%
Nov-14-19 08:00AM  CymaBay Therapeutics to Present at Upcoming Investor Conferences GlobeNewswire
Nov-05-19 04:10PM  CymaBay Reports Third Quarter 2019 Financial Results and Provides Corporate Update GlobeNewswire
Nov-04-19 08:00AM  CymaBay Therapeutics Reaches Target Enrollment in the ENHANCE Global Phase 3 Study Evaluating Seladelpar for Primary Biliary Cholangitis GlobeNewswire +8.47%
Nov-03-19 08:11AM  Is CymaBay Therapeutics, Inc.'s (NASDAQ:CBAY) CEO Salary Justified? Simply Wall St.
Oct-28-19 08:00AM  CymaBay Therapeutics to Report Third Quarter 2019 Financial Results on Tuesday, November 5 GlobeNewswire
Oct-18-19 10:23AM  These 24 Bay Area drug and diagnostics companies quietly raised nearly $3B this year American City Business Journals
Oct-14-19 08:00AM  CymaBay Therapeutics to Present at the H.C. Wainwright 3rd Annual NASH Investor Conference GlobeNewswire
Oct-01-19 04:05PM  CymaBay Therapeutics Announces Presentations at The Liver Meeting® 2019 GlobeNewswire
Sep-30-19 08:00AM  CymaBay Therapeutics to Present at the 2019 Cantor Global Healthcare Conference GlobeNewswire
Sep-28-19 09:35AM  Investors Who Bought CymaBay Therapeutics (NASDAQ:CBAY) Shares Three Years Ago Are Now Up 168% Simply Wall St.
Sep-17-19 04:30PM  CymaBay Therapeutics Announces Departure of Chief Medical Officer GlobeNewswire
Sep-16-19 06:28AM  Investors in CymaBay Therapeutics Need Patience and Discipline TheStreet.com
Sep-10-19 03:31PM  Edited Transcript of CBAY earnings conference call or presentation 7-Aug-19 8:30pm GMT Thomson Reuters StreetEvents
Sep-03-19 08:00AM  CymaBay Therapeutics to Present at Upcoming Investor Conferences in September GlobeNewswire
Aug-23-19 12:36PM  What You Must Know About CymaBay Therapeutics, Inc.'s (NASDAQ:CBAY) Beta Value Simply Wall St.
Aug-12-19 08:46AM  3 Hot Healthcare Stocks That Wont Break the Bank TipRanks
Aug-09-19 02:01PM  CymaBay Therapeutics, Inc. (CBAY) Q2 2019 Earnings Call Transcript Motley Fool
Aug-07-19 04:10PM  CymaBay Reports Second Quarter 2019 Financial Results and Provides Corporate Update GlobeNewswire
Aug-05-19 08:00AM  CymaBay Therapeutics Strengthens Management Team with Appointment of Janet Dorling as Chief Commercial Officer GlobeNewswire -6.93%
Jul-31-19 04:23PM  CymaBay Therapeutics to Report Second Quarter 2019 Financial Results on Wednesday, August 7 GlobeNewswire
Jun-18-19 08:00AM  CymaBay Therapeutics Announces IND to Commence a Clinical Study of Seladelpar to Treat Primary Sclerosing Cholangitis GlobeNewswire +8.16%
Jun-17-19 02:15PM  Bulls Walk the Market Up Slowly, but Keep One Eye on Fed TheStreet.com
10:08AM  Health Care Digest: Not-so-secret target of new UC-GSK alliance, East Bay toolmaker's big round and more American City Business Journals
08:00AM  CymaBay Therapeutics to Participate in the Raymond James Life Sciences and MedTech Conference GlobeNewswire
Jun-13-19 11:51AM  Hedge Funds Have Never Been This Bullish On CymaBay Therapeutics Inc (CBAY) Insider Monkey +9.40%
Jun-12-19 06:27PM  CymaBay Down on Dismal Interim Data From Mid-Stage NASH Study Zacks
09:27AM  Biotech Stock Roundup: Celgene Submits MS Drug to FDA, INSY & CBAY Crash Zacks
08:53AM  CymaBay Therapeutics Stock Plunged. Heres Why It Could Be Time to Buy Barrons.com
07:34AM  The Daily Biotech Pulse: Nuvectra Files For Expanded Label For Algovita SCS, Axovant Earnings, FDA Nod For Aratana Benzinga
Jun-11-19 12:25PM  Here's Why CymaBay Therapeutics Collapsed Today Motley Fool -45.45%
09:02AM  How Much Are CymaBay Therapeutics, Inc. (NASDAQ:CBAY) Insiders Spending On Buying Shares? Simply Wall St.
08:58AM  CymaBay Therapeutics stock down 43% after NASH trial data disappoint investors MarketWatch
08:30AM  CymaBay Therapeutics Plummets 40% Following Liver Disease Data Benzinga
07:00AM  CymaBay Therapeutics Reports Topline 12-Week Data from an Ongoing Phase 2b Study of Seladelpar in Patients with Nonalcoholic Steatohepatitis GlobeNewswire
Jun-10-19 02:50PM  Steven Cohen Takes an Interest in CymaBay Therapeutics GuruFocus.com
May-22-19 10:26AM  Options Traders Expect Huge Moves in CymaBay Therapeutics (CBAY) Stock Zacks
May-20-19 04:01PM  CymaBay Therapeutics Presents Data in Patients with Primary Biliary Cholangitis at DDW 2019 GlobeNewswire
May-18-19 09:50AM  The Week Ahead In Biotech: Conferences, PDUFA Dates, Clinical Trial Readouts And IPOs Benzinga
May-16-19 09:07PM  Edited Transcript of CBAY earnings conference call or presentation 8-May-19 8:30pm GMT Thomson Reuters StreetEvents
May-09-19 08:31PM  Hedge Funds Have Never Been This Bullish On CymaBay Therapeutics Inc (CBAY) Insider Monkey
May-08-19 04:05PM  CymaBay Reports First Quarter 2019 Financial Results and Provides Corporate Update GlobeNewswire
08:00AM  CymaBay Therapeutics Announces Multiple Presentations at DDW 2019 GlobeNewswire
May-02-19 03:43PM  Genfit, Cymbay Hope to Crack Large Liver Disease Market GuruFocus.com
Apr-30-19 08:00AM  CymaBay Therapeutics to Report First Quarter 2019 Financial Results on Wednesday, May 8 GlobeNewswire
Apr-12-19 09:04AM  If You Had Bought CymaBay Therapeutics (NASDAQ:CBAY) Stock Three Years Ago, You Could Pocket A 703% Gain Today Simply Wall St.
08:00AM  CymaBay Therapeutics Presents Positive Phase 2 Data for Seladelpar in Patients with Primary Biliary Cholangitis at the International Liver Congress 2019 GlobeNewswire
Mar-27-19 08:00AM  CymaBay Therapeutics Announces Multiple Presentations During The International Liver Conference 2019 GlobeNewswire
Mar-25-19 07:00AM  Market Trends Toward New Normal in Louisiana-Pacific, The Michaels Companies, VEREIT, CymaBay Therapeutics, CareDx, and Harsco Emerging Consolidated Expectations, Analyst Ratings GlobeNewswire
Mar-12-19 08:00AM  CymaBay Therapeutics to Present at Upcoming Investor Conferences in March GlobeNewswire
Mar-11-19 04:05PM  CymaBay Announces Closing of Public Offering of Common Stock, Including Full Exercise of Underwriters Option to Purchase Additional Shares GlobeNewswire
Mar-06-19 08:00AM  CymaBay Announces Pricing of Public Offering of Common Stock GlobeNewswire -5.20%
Mar-05-19 08:26PM  Edited Transcript of CBAY earnings conference call or presentation 28-Feb-19 9:30pm GMT Thomson Reuters StreetEvents
04:01PM  CymaBay Announces Proposed Public Offering of Common Stock GlobeNewswire
Feb-28-19 11:24PM  CymaBay Therapeutics Inc (CBAY) Q4 2018 Earnings Conference Call Transcript Motley Fool
04:05PM  CymaBay Reports Fourth Quarter and Fiscal Year End 2018 Financial Results and Provides Corporate Update GlobeNewswire
Feb-22-19 07:40AM  Factors of Influence in 2019, Key Indicators and Opportunity within Apple, United Continental, ImmunoGen, CymaBay Therapeutics, Granite Construction, and Flotek Industries New Research Emphasizes Economic Growth GlobeNewswire +11.39%
Feb-21-19 08:00AM  CymaBay Therapeutics to Report Fourth Quarter and Fiscal 2018 Financial Results on Thursday, February 28 GlobeNewswire
Feb-20-19 08:00AM  CymaBay Therapeutics to Present at the 8th Annual SVB Leerink Global Healthcare Conference GlobeNewswire
Feb-19-19 08:00AM  CymaBay Therapeutics Announces Early Enrollment of a Phase 2b Study of Seladelpar in Patients with Nonalcoholic Steatohepatitis GlobeNewswire
Feb-15-19 08:00AM  CymaBay Therapeutics Announces Seladelpar Granted Breakthrough Therapy Designation by the FDA for the Treatment of Primary Biliary Cholangitis GlobeNewswire
Feb-07-19 09:20AM  CymaBay Therapeutics, Inc. (NASDAQ:CBAY): What Does Its Beta Value Mean For Your Portfolio? Simply Wall St.
Jan-02-19 08:00AM  CymaBay Therapeutics to Present at the 37th Annual J.P. Morgan Healthcare Conference GlobeNewswire
Dec-21-18 09:29AM  Have Insiders Been Buying CymaBay Therapeutics, Inc. (NASDAQ:CBAY) Shares? Simply Wall St.
Dec-12-18 12:10AM  Hedge Funds Are Buying CymaBay Therapeutics Inc (CBAY) Insider Monkey
Nov-27-18 08:25AM  Report: Exploring Fundamental Drivers Behind ForeScout Technologies, GNC, Dova Pharmaceuticals, CymaBay Therapeutics, Adesto Technologies, and Clearside Biomedical New Horizons, Emerging Trends, and Upcoming Developments GlobeNewswire
Nov-20-18 08:00AM  CymaBay Therapeutics to Participate in Upcoming Investor Conferences GlobeNewswire
Nov-19-18 05:31AM  Edited Transcript of CBAY earnings conference call or presentation 6-Nov-18 9:30pm GMT Thomson Reuters StreetEvents -7.56%
Nov-13-18 08:00AM  CymaBay Therapeutics Presents Positive Results from its Ongoing Phase 2 Study of Seladelpar in Patients with PBC at The Liver Meeting® 2018 GlobeNewswire -14.19%
Nov-06-18 04:10PM  CymaBay Reports Third Quarter 2018 Financial Results and Provides Corporate Update GlobeNewswire
Oct-30-18 04:05PM  CymaBay to Report Third Quarter 2018 Financial Results on Tuesday, November 6 GlobeNewswire +6.42%
08:00AM  CymaBay Announces the Initiation of the Seladelpar Global Phase 3 Registration Study (ENHANCE) for the Treatment of Primary Biliary Cholangitis and Additional Corporate Updates GlobeNewswire
Oct-22-18 11:57AM  Weekly CEO Buys Highlight GuruFocus.com
Oct-10-18 07:40AM  Report: Developing Opportunities within Brunswick, Pebblebrook Hotel Trust, Avaya, Braskem S.A, CymaBay Therapeutics, and The Blackstone Group Future Expectations, Projections Moving into 2018 GlobeNewswire
Oct-03-18 09:00AM  CymaBay Therapeutics Announces Additional Positive Results from its Ongoing Phase 2 Study of Seladelpar in Patients with PBC will be Presented During the Late-Breaking Session at The Liver Meeting® GlobeNewswire +7.82%
Sep-24-18 08:00AM  CymaBay Therapeutics to Participate in Upcoming Investor Conferences in October GlobeNewswire
Sep-17-18 03:40PM  Oppenheimers 7 Top Stock Picks for September Kiplinger
Aug-28-18 10:50AM  Oppenheimers 7 Top Stock Picks for September InvestorPlace
Aug-26-18 11:55PM  Edited Transcript of CBAY earnings conference call or presentation 9-Aug-18 8:30pm GMT Thomson Reuters StreetEvents
Aug-14-18 08:00AM  CymaBay Therapeutics to Participate in Upcoming Investor Conferences in August and September GlobeNewswire
CymaBay Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and providing therapies to treat liver and other chronic diseases. Its lead product candidate is seladelpar, a selective agonist of peroxisome proliferator-activated receptor delta, which has completed Phase II clinical study for the treatment of primary biliary cholangitis, as well as patients with nonalcoholic steatohepatitis. The company also develops MBX-2982, a selective orally-active G protein-coupled receptor agonist that interacts with bioactive lipids known to stimulate glucose-dependent insulin secretion for the treatment of gut/liver disease. Its preclinical stage product candidate is CB-001, a G protein-coupled receptor for omega-3 fatty acids, such as docosahexaenoic acid for the treatment of gut/liver disease. It has development and licensing agreement with Janssen Pharmaceuticals, Inc. to develop and discover undisclosed metabolic disease target agonists for the treatment of type II diabetes and other disorders; and a license agreement with DiaTex, Inc. to develop and commercialize therapeutic products comrprising halofenate and its enantiomers, derivatives, and analogs for the treatment of diseases. The company was formerly known as Metabolex, Inc. CymaBay Therapeutics, Inc. was incorporated in 1988 and is headquartered in Newark, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Shah SujalChief Executive OfficerOct 10Buy4.305,00021,500120,000Oct 15 08:20 AM
Shah SujalChief Executive OfficerSep 23Buy5.553,10017,205115,000Sep 24 08:56 AM
Shah SujalChief Executive OfficerSep 20Buy5.501,90010,450111,900Sep 24 08:56 AM